The submucosal injections market is estimated to secure a valuation of US$ 1.3 Billion in 2023 and is estimated to rise to US$ 2.3 Billion by 2033. The market is anticipated at a CAGR of 5.8% during the forecast period. The factors accelerating the demand for submucosal injections are as follows-
Increased patient pool for endoscopic submucosal dissection systems prompting the demand for submucosal injections market during the forecast period. Increased application of submucosal injections in hospitals and surgical centers in different procedures is driving the market growth
Increasing demand for submucosal injections in endoscopic procedures, and increased treatment rate of early cancer detection. Other factors driving the submucosal injections market include increasing advances in the medical sector along with increased consumer awareness. The increased aging population prone to chronic diseases also drives the submucosal injection market growth. Also, the increased application of submucosal lifting agents like Eliview and ORISE gel, Normal saline, and dextrose water drives the demand for the submucosal injections market.
North America is expected to hold the largest share of the submucosal injections market. Increased application of submucosal injections in countries like the USA and Canada is likely to drive market growth in the region. Increased cases of cancer and the presence of well-developed healthcare infrastructure drive market growth in North America.
Europe is expected to witness significant growth in the submucosal injections market during the forecast period owing to the increased number of patients for gastro, colorectal and oesophageal cancer. Increased technological advances in healthcare
Asia Pacific market is expected to witness exponential growth with an increased number of endoscopic procedures performed and an increased number of cancer patients.
Some of the leading players operating in the submucosal injections market are Biospace Inc, Ovesco Endoscopy AG, GI Supply Cosmo Pharmaceuticals N.V., Fujifilm Medical Systems, Pharma Science Inc, Medtronic Plc, Boston Scientific, Aries Pharmaceuticals, Sumitomo Bakelite Co, ERBE Elektromedizin GmBH, Zeon Medical, Olympus Corporation, Fujifilm Medical system among others
Submucosal injection market players are heavily investing in research & development activities to increase their product portfolio. The submucosal injection market is witnessing an increase in partnerships and mergers & acquisitions.
For instance, in September 2022- Olympus announced the USA distribution of EndoClot® Submucosal Injection Solution and EndoClot® Polysaccharide Hemostatic Spray. Both of these products are developed by Endoclot Plus Inc.
The submucosal injection market is expected to grow in the coming years. The increasing demand for submucosal injections for endoscopic procedures is expected to drive market growth during the forecast period. Also, the availability of submucosal injections in hospital pharmacies, retail pharmacies, and online stores increases the sales of the market. Several start-ups have entered the submucosal injections market with innovative products and technology.
For instance, AscentX Medical is a startup founded in 2008. They developed minimally invasive endoscopic injection procedures for the treatment of different medical conditions. The G25 bulking agent is for the treatment of Gastroesophageal reflux disease.
| Data Point | Key statistics |
|---|---|
| Expected Market Value in 2023 | US$1.3 Billion |
| Projected Market Value in 2033 | US$ 2.3 Billion |
| Growth Rate (2023 to 2033) | CAGR of 5.8% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to the latest research by FMI, submucosal injections is set to witness a 7.3% growth during the year 2021-2031. The global demand for submucosal injections is expected to grow at a moderate pace during the forecast period. The submucosal injections are required principally during the endoscopic mucosal resection techniques.
They are an indispensable part of endoscopic submucosal dissection. Thus the submucosal injections are expected to grow in value by commonly being used in the treatment of diseases such as cancers (esophageal, small intestine and gastric), polyps in the colon and Barrett’s esophagus. The most common submucosal agents are dextrose water, hydroxypropyl methylcellulose, normal saline, hyaluronic acid, hydroxyethyl starch and Orise gel.
Submucosal injections are an indispensable part of endoscopic submucosal dissection. Thus the submucosal injections are expected to grow in value by commonly being used in the treatment of diseases such as cancers (esophageal, small intestine and gastric), polyps in the colon and Barrett’s esophagus.
The use of these injections thus accounts for the minimization of adverse effects and untangles polypectomy. The rise in the application of submucosal injections is attributed to the increasing cases of several cancer types and their use in surgeries for the helpful removal of cancer cells before their growth. The factor of this technique being less invasive allows greater adoption of submucosal injections.
Principal Consultant
The augmentative factors which are expected to propel the development of submucosal injections are the increasing demand for endoscopic procedures, especially in the developed economies. Additionally, the rise in the number of patients with the intention of seeking treatment for early stage stomach cancer or premature cancer has also assisted with the increased growth and demand for submucosal injections.
Also, the introduction of new submucosal lifting agents such as, the development of Eleview by Cosmo Pharmaceuticals N.V., which is a ready-to-use and safe submucosal lifting agent, has led to advanced research and adoption of submucosal injections.
The submucosal injections value is likely to experience lucrative growth in the region of North America. The countries USA and Canada amount to the largest share in the submucosal injections application. According to the USA National Cancer Institute, cancer incidence rate is 442.4 per 100,0000 men and women per year.
The increasing cases of several cancer types which include gastro, esophageal and colorectal cancers in these countries has accounted for the increase in demand of submucosal injections. Additionally, the demand is also gaining traction because of advanced healthcare infrastructure as well as favorable reimbursement policies in North America.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The Europe submucosal injections sales is set to gain significant traction due to the increasing healthcare expenditure. The incidence rate of primarily esophageal cancer in the United Kingdom and Netherlands is highly standardized. The advancement of technology in terms of treatment of early stomach cancer, intestinal cancer and esophageal cancer is set to advance the European submucosal injections growth.
The key manufacturers of the submucosal injections are
The key players use patented advancements and hold a dominating position in production and marketing of submucosal injections. Moreover, high R&D activities and new product advancements cater to the company rank and position.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments.
The report also maps the qualitative impact of various market factors on market segments and geographies.
Explore Healthcare Insights
View Reports
Submucosal Injections Market
